Consultant Clinical Oncologist GU & Sarcoma
| Posting date: | 13 May 2024 |
|---|---|
| Salary: | £99,532.00 to £131,964.00 per year |
| Additional salary information: | £99532.00 - £131964.00 a year |
| Hours: | Full time |
| Closing date: | 03 June 2024 |
| Location: | Manchester, M20 4BX |
| Company: | NHS Jobs |
| Job type: | Permanent |
| Job reference: | C9413-24-0357 |
Summary
This post is for 10 Programmed Activities (PAs) per week to work within the Clinical Oncology urology and sarcoma group and proton beam therapy team. The outpatient clinics will be held at both at The Christie main site and Stepping Hill Hospital Role Purpose This is a replacement 10PA post. It is envisaged that the post-holder will have clinical commitments in both Urological and Sarcoma oncology, being actively involved in these disease groups, as well as being involved in the national delivery of proton beam therapy (PBT) for complex bone and soft tissue sarcomas. The appointee will be expected to develop a significant interest in both GU and Sarcoma delivering both radiotherapy, and systemic therapy. The appointee will be a member of the South sector (Stockport-Tameside-Macclesfield) urology MDT and also the sarcoma MDT. As such they will be expected to do two weekly clinics at Christie (one sarcoma and one urology), a weekly GU peripheral clinic at Stepping Hill Hospital and participate in person at both weekly MDTs. One is presently at Stepping Hill Hospital but may later move to Christie Hospital (GU) and the other is the weekly GMOSS MDT hosted by MFT DUTIES AND RESPONSIBILITIES Urology The appointee will be expected to develop a significant urology interest delivering both radiotherapy and systemic therapy. The post involves a weekly peripheral clinic at Stepping Hill Hospital and a clinic at Christie. The peripheral clinic will involve seeing new and complex follow up patients and having oversight of a parallel nurse led clinic delivering novel hormone therapies. At present any patients requiring intravenous systemic therapy will be transferred to the Christie site to receive this treatment. The post holder will join a large team of 8 Clinical Oncology consultants specialising in Urological cancer these are: Dr James Wylie (lead Clinician) Dr Ananya Choudhury Dr Ruth Conroy Dr Andrew Hudson Dr John Logue Dr Maria Serra Dr Yee Pei Song Dr Anna Tran The appointee will serve the South sector MDT (Stockport-Tameside-Macclesfield) together with Dr Logue. This will include attendance at the specialist Urology MDT. In the last year the urology team have seen approximately 1100 new patients. The south sector uro-oncology service is an established team comprising 2 clinical oncologists, 12 urologists (3 performing level 2 surgery), 2 pathologists, 3 radiologists and clinical nurse specialists on all 3 sites in addition to an MDT co-ordinator. The Clinical Oncology Urology group provide a comprehensive range of treatment options including VMAT/IGRT, LDR/HDR brachytherapy, prostate SABR, oligometastatic SABR and delivery of radionuclide therapies e.g. Ra223. The provision of chemotherapy for prostate and urothelial cancers is delivered by the clinical oncology team with renal cancer and testicular cancer systemic therapies undertaken by the medical oncology team. The urology group has an established record in radiotherapy related research, the delivery of clinical trials and has a broad portfolio of commercial and academic phase 2-3 studies. Radiotherapy related research is led by Professor Ananya Choudhury and the urology team have monthly multi-disciplinary radiotherapy research meetings with regular attendance by radiographers, physicists and clinicians. There is also a monthly research seminar at which all on going research is presented by surgical, radiotherapy and systemic teams. Systemic and novel agent clinical trials are led by Dr A Hudson. The GU clinical oncology group has an active research programme with a Phase I/II/III trial portfolio delivering research studies to ~150-200 patients per year. The research team comprises 5 experienced research nurses and 6 clinical trials administrators. This role may include the setting up of radiotherapy trials or clinical developments involving advanced radiotherapy techniques such as SABR, or MR Linac. Sarcoma The postholder will be joining the Sarcoma clinical oncology consultant team and this consists of the following doctors: Dr James Wylie (Lead Clinician) Dr Mohammed Khalid Abutaleb Dr Abiola Fatimilehin These consultants who share responsibility for the delivery of radiotherapy for bone and soft tissue sarcoma. There is a weekly multidisciplinary sarcoma clinic involving Consultant Onco-plastic surgeons (Mr D Mowatt and Mr Damir Kosutic). Approximately 100 cases per annum receive radical radiotherapy. Dr A Lee and Dr Hameed share responsibility for any chemotherapy delivered for sarcoma and they run a weekly parallel clinic. Approximately 150 new cases of sarcoma are currently seen at The Christie per year. The Greater Manchester and Oswestry Sarcoma Service (GMOSS) is based primarily around three Hospitals, namely Manchester University NHS Foundation Trust (MFT), Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust (RJAH), and The Christie NHS Foundation Trust. GMOSS provide specialist care for patients with all types and stages of soft tissue and bone sarcoma residing in the Greater Manchester, Cheshire, parts of Greater Midlands, and North Wales. Patients with bone sarcoma and teenage and young adult patients with sarcoma residing in the Lancashire and South Cumbria Cancer Network (LSCCN) are referred into GMOSS. The core service comprises five sarcoma surgeons, two medical oncologists, two clinical oncologists, one dedicated TYA oncologist, three musculo-skeletal radiologists, two specialist sarcoma pathologists plus two clinical nurse specialists (CNS) at Christie as well as nurses at MFT and Oswestry all with a special interest in sarcoma. The sarcoma service screens and recruits patients to clinical trials and is assisted by a clinical trials nurse. A core weekly multi-disciplinary team meeting (MDT) between the sites is held where all confirmed new, highly suspected or recurrent sarcoma cases are discussed to formulate a management plan. The MDT is video linked between the three sites The team is also responsible for delivery of proton beam therapy (PBT) for TYA and adult patients fulfilling the NHS criteria for this treatment. Broadly this includes patients with para-spinal and spinal sarcomas, truncal and pelvic Ewings and complex head and neck sarcomas including rhabdomyosarcoma. The well supported team structure can provide training and mentorship in PBT planning and delivery and prior experience is not a pre-requisite. The postholder will be expected to see approximately 160 new patients per year across both disease sites.